Tirzepatide Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Tirzepatide evidence and protocol review

Metabolic Research peptide Injection solutionLyophilized research material needs_revision Best effort · source review pending

Also known as: Mounjaro, Zepbound, LY3298176

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg labeled weekly doses, 30 mg research vial

Storage

Refrigerate 2-8 deg C before first use; limited room-temperature window after first use per product labeling - verify against current FDA label.

Solubility

Form, salt, and formulation dependent; verify the lot-specific COA

Best-Effort Research Profile

Tirzepatide is a dual GIP/GLP-1 receptor co-agonist. SURMOUNT-1 (NEJM) reported 20.9% mean body-weight reduction at the highest dose (72 weeks) versus 3.1% placebo. The head-to-head SURMOUNT-5 trial (NEJM, published via peer review; coverage confirmed May 2025-2026) reported 20.2% mean weight loss for tirzepatide versus 13.7% for semaglutide at 72 weeks in adults with obesity/overweight and comorbidities - the first direct randomized comparison between the two agents. Approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (obesity, 2023).

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

~5 days

Onset

Progressive weight/glycemic effect over weeks as dose is titrated

Administration Routes (Research)

Subcutaneous (SC)

Reported Research Effects

Superior weight reduction vs. semaglutide in head-to-head RCT (SURMOUNT-5)
Improves glycemic control via dual incretin pathway
Reduces appetite and slows gastric emptying

Reported Research Side Effects

Human safety, pharmacokinetics, and interaction data are incomplete

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Route-Specific Research Protocols

Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.

Label / guideline Human study Community only Preclinical only Not established

Subcutaneous (SC) Label / guideline

Weeks 1-4: 2.5 mg once weekly; week 5 onward: 5 mg once weekly; if additional effect is needed, increase by 2.5 mg only after at least 4 weeks at the current dose through 7.5, 10, 12.5, and 15 mg maximum

Frequency / timing: Weekly
Duration / setting: Label-directed escalation then maintenance
Technique: SC
Evidence: Regulatory label

Context: current ZEPBOUND prescribing information

Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.

Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.

Source 1

Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.

Research Notes

A 30 mg lyophilized vial is not an FDA-approved presentation. Product labeling, indication, and device concentration control dosing.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources Under Review

ZEPBOUND tirzepatide prescribing information — DailyMed (NIH)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Where to Source Tirzepatide

The following are third-party vendor links for this compound, provided for reference only. Some may be affiliate links, and prices/coupons are entered manually and may not always reflect the vendor's current listing. No affiliation, endorsement, or product claim is implied. Verify price, coupon validity, and product specifications directly on the vendor's site before purchase.

COA verified

Tirzepatide

MG: 20-mg MG: 30-mg MG: 60-mg G1P-2 TZ 20mg — Full 10-Vial Kit G1P-2 TZ 30mg — Full 10-Vial Kit G1P-2 TZ 60mg — Full 10-Vial Kit

Hacker Peptides

In stock

COA Batch A2TZ201125

$75.00 $40.25

-46.33%

Shop ↗

Third-party links — not affiliated with this site. Not a recommendation for human use. Research compounds are for laboratory and educational use only.

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.